BPC-157 for gut health: the animal evidence and the missing human trials

The short answer: BPC-157's gut evidence is the strongest part of its animal record and nearly empty in people. In rats, BPC-157 healed stomach ulcers, colitis, fistulas, and surgical bowel joins, and reversed weight loss after most of the small bowel was removed. [1] [3] [6] But no controlled human study of BPC-157 for any gut condition has published results, and a 2026 review found no completed phase II trial in the published record. [10]

Below is what the GI studies found, the few human reports, how it compares with KPV, and which gut treatments have human evidence.

Why is BPC-157 linked to gut health?

BPC-157 is a synthetic 15 amino acid fragment of a protein found in human gastric juice, and it was first studied as an anti-ulcer agent. The discovering group describes it as stable in gastric juice and active by mouth as well as by injection, which is why so much of its research is on the digestive tract. [1] [2]

That origin does not make it a gut supplement. It is an unapproved drug candidate whose gut data come almost entirely from rodents.

What did BPC-157 do in animal gut studies?

The GI literature is large, consistent, and mostly from one laboratory in Zagreb:

• Ulcers. Reviews by the group summarize protection against stomach and intestinal lesions caused by alcohol and anti-inflammatory drugs such as NSAIDs in rats. [1]
• Colitis. In rats with chemically induced colitis, BPC-157 given by injection or in drinking water healed the colitis and a colon-to-colon surgical join, which controls could not heal. [3] In an ischemic colitis model, applying BPC-157 to the injured colon restored blood vessel filling and preserved the lining. [4]
• Fistulas. In a colon-to-skin fistula model, BPC-157 by injection or drinking water sped closure of both the colon and skin defects; sulfasalazine was only moderately effective, and a corticosteroid made healing worse. [5]
• Short bowel. After most of the small bowel was removed, treated rats gained weight above their preoperative level over 4 weeks while controls lost weight, and villus height and gut wall thickness increased. [6]
• Surgical joins. BPC-157 improved healing of a join between two segments of small bowel over 14 days. [7]

The same group proposes that these effects run through the nitric oxide system, blood vessel growth, and a brain-gut axis. [8] These mechanisms are documented in rodents only. Independent replication outside the originating group remains limited across the BPC-157 literature, which is the main reason we grade it animal only. [9]

Is there human evidence for BPC-157 and gut health?

Very little, and none that settles the question:

• The inflammatory bowel disease program. Papers from the discovering group repeatedly describe BPC-157, under the development code PL 14736, as tested and safe in clinical trials for inflammatory bowel disease, and one review says it was tested only in phase II. [2] We found no full peer-reviewed report of those trial results. A 2026 review of the drug-development record found no completed phase II trial and no pharmaceutical-grade formulation in the published literature. [10]
• The pancreatitis patients. A 2011 study is sometimes cited as human gut data. It combined rat experiments with esophageal pressure measurements in patients with acute pancreatitis. The patients were measured, not treated: only the rats received BPC-157. [11]

The rat models also differ from human disease in a basic way. Most create an acute injury with a chemical or a scalpel and then measure healing over days to weeks, as in the colitis and bowel resection studies. [3] [6] Crohn disease and ulcerative colitis are chronic, relapsing immune diseases that run for years. A peptide that speeds healing of a fresh injury in a rat may or may not change the course of a lifelong condition, and only a human trial can show which.

The three human pilot reports published since 2021 studied knee pain, interstitial cystitis, and intravenous safety, not the gut. Our BPC-157 human studies post lists each with its sample size and limits.

Why is the gut evidence graded animal only?

Our BPC-157 record grades the whole evidence base animal only, and the gut studies are no exception. The grade reflects what kind of study exists, not how many. The gut papers above are rodent experiments or reviews of them, and a 2025 systematic review of BPC-157 in orthopaedic sports medicine shows the same pattern elsewhere: of 36 studies it included, 35 were preclinical and one was clinical. [22] The 2026 drug-development review counted fewer than 30 people across three uncontrolled human pilots, none of which used a standardized pharmaceutical preparation. [10]

A higher grade would need a controlled human trial with a named gut outcome, such as endoscopic healing in ulcerative colitis or fistula closure in Crohn disease. None has been published.

Does BPC-157 help IBS or leaky gut?

IBS. We found no study of BPC-157 for irritable bowel syndrome in animals or people. The rat studies model wounds, ulcers, and surgical injury. IBS is diagnosed by symptom criteria and managed as a disorder of gut-brain interaction, which is a different problem. [15] Our irritable bowel syndrome page grades BPC-157 animal only, with no IBS data.

Leaky gut. The claim that BPC-157 repairs "leaky gut" traces to a 2020 review, co-authored by the discovering group's lead researcher, that proposed BPC-157 could stabilize intestinal permeability after NSAID injury. [12] It is a hypothesis built on laboratory and animal work. No study has measured gut permeability in people after BPC-157.

Does BPC-157 survive digestion when taken by mouth?

Gut claims often come with capsules, so the oral question matters. The discovering group reports that BPC-157 is unusually stable in gastric juice and active by mouth in rats. [1] What happens in people is not known. The only formal pharmacokinetic study gave BPC-157 by intravenous and intramuscular injection to rats and dogs, not by mouth. It found a plasma half-life under 30 minutes, fast breakdown into small peptide fragments and amino acids, and excretion in urine and bile. [19] The 2026 review describes the human pharmacokinetic profile as critically undercharacterized and notes that no pharmaceutical-grade formulation has been developed or validated. [10]

So a capsule sold for gut health rests on rat studies of a laboratory preparation, not on any measurement of what reaches the human bowel. The oral BPC-157 post covers those claims in more detail.

What are the safety unknowns for gut use?

The human safety record is too small to rule out uncommon harms. The pilot reports described no adverse events, but they were uncontrolled and small. [10] The intravenous safety pilot, for example, followed two healthy adults for three days. [21]

One concern is specific to how BPC-157 is thought to work. In cell and rat experiments by an independent group, BPC-157 promoted new blood vessel growth through the VEGFR2 receptor. [20] Blood vessel growth helps wounds heal, and it is also how tumors grow, which is why our record lists active cancer or a history of cancer as a caution. That risk is theoretical: it has not been shown in people, and it has not been ruled out either.

How does BPC-157 compare with KPV for gut inflammation?

KPV, a three amino acid fragment of alpha-MSH, is the other peptide most marketed for gut inflammation. In mouse models of inflammatory bowel disease, KPV reduced inflammation and colitis severity. [13] Like BPC-157, it has no published human trial for any gut condition, and PCAC recommended both for the 503A bulks list in July 2026 without a final rule yet. [16] Our BPC-157 vs KPV comparison and the KPV page set them side by side. No study has tested the two together.

What has human evidence for gut conditions?

For irritable bowel syndrome with constipation, linaclotide is an FDA approved peptide. In a 26-week phase 3 trial, 33.7% of patients met the combined pain and bowel movement responder endpoint versus 13.9% on placebo. [14] The 2021 American College of Gastroenterology guideline recommends it for IBS with constipation, alongside a limited trial of a low FODMAP diet and gut-directed psychotherapy. [15]

For Crohn disease and ulcerative colitis, no peptide has human trial support. The treatments backed by large trials, from aminosalicylates to biologics, are summarized on our inflammatory bowel disease page. Anyone with a diagnosed bowel disease should not swap a specialist plan for an unapproved peptide.

Is BPC-157 legal to use for gut health?

BPC-157 is not an FDA approved drug. PCAC's July 2026 recommendation for the 503A bulks list is advisory; until FDA publishes a final rule, BPC-157 is not on the list, and a 503A pharmacy has no federal basis to compound it from bulk, whether as capsules or injections. [16] [17] Follow the BPC-157 regulatory timeline and the state legal guides. Products sold as research chemicals are not lawful for human use. WADA prohibits BPC-157 at all times. [18]

The BPC-157 cost page explains why there is no lawful compounded price to compare. If a lawful path opens, how to get peptides prescribed explains what a legitimate prescription involves. Clinics that offer BPC-157 as part of peptide therapy are offering a substance with no lawful compounding basis yet.